Akoya Biosciences and NeraCare Enter into an Exclusive Agreement to Enable Personalized Therapy Selection for Early-Stage Melanoma Patients tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
1. The pathological response rate had an OR of 3.16 when comparing neoadjuvant dual vs single checkpoint inhibitors. 2. The grade 3-4 immune-related adverse event rate had an OR 3.75 when comparing neoadjuvant dual vs single checkpoint inhibitors. Evidence Rating Level: 1 (Excellent) Study Rundown: Adjuvant therapy in resected advanced melanoma with immune checkpoint inhibitors
A new AI tool may help clinicians determine which early stage melanoma patients would likely benefit from aggressive treatment even at the onset of the disease.